Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-19

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

NCT05193604

Pancreatic Carcinoma

TERMINATED PHASE1

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

NCT07165951

Metastatic Pancreatic Ductal Adenocarcinoma

RECRUITING PHASE3

A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)

NCT06962267

Pancreatic Cancer

RECRUITING PHASE2

Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer

NCT04718701

Pancreatic Neoplasm Metastatic Pancreatic Cancer Locally Advanced Pancreatic Adenocarcinoma

UNKNOWN PHASE2

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

NCT06051851

Pancreatic Adenocarcinoma Metastatic

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TQB2868 injection+Gemcitabine injection+ Albumin paclitaxel injection+ Anlotinib capsules

Treatment period:

TQB2868 injection combined with Gemcitabine injection and Albumin paclitaxel injection, 28 days as a treatment cycle.

Oral administration of Anlotinib capsules tablets once a day, for 2 weeks followed by a 1 week untreated recovery phase.

Maintenance period:

TQB2868 injection combined with Gemcitabine injection, 21 days as a treatment cycle.

Oral administration of Anlotinib capsules tablets once a day, for 2 weeks followed by a 1 week untreated recovery phase.

Group Type EXPERIMENTAL

TQB2868 injection

Intervention Type DRUG

TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.

Gemcitabine injection

Intervention Type DRUG

Gemcitabine injection

Albumin paclitaxel injection

Intervention Type DRUG

Albumin paclitaxel injection

Anlotinib capsules

Intervention Type DRUG

Anlotinib capsules

TQB2868 injection+Gemcitabine injection +Albumin paclitaxel injection

Treatment period TQB2868 injection combined with Gemcitabine injection and Albumin paclitaxel injection, 28 days as a treatment cycle.

Maintenance period TQB2868 injection combined with Gemcitabine injection, 21 days as a treatment cycle.

Group Type EXPERIMENTAL

TQB2868 injection

Intervention Type DRUG

TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.

Gemcitabine injection

Intervention Type DRUG

Gemcitabine injection

Albumin paclitaxel injection

Intervention Type DRUG

Albumin paclitaxel injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TQB2868 injection

TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.

Intervention Type DRUG

Gemcitabine injection

Intervention Type DRUG

Albumin paclitaxel injection

Intervention Type DRUG

Anlotinib capsules

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must voluntarily participate in the study and sign the informed consent form.
* Aged between 18 and 75 years (inclusive) at the time of signing the informed consent form.
* Diagnosed with pancreatic ductal adenocarcinoma through histological or cytological confirmation.
* Have at least one evaluable metastatic lesion according to RECIST 1.1 criteria;
* No prior systemic anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, targeted therapy, or immunotherapy). Patients who experience disease progression more than 6 months after completing neoadjuvant or adjuvant therapy are eligible.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, with an expected survival of more than 3 months.
* Normal major organ function.
* Patients must use reliable contraception during the study period and for 6 months after the end of the study period; Female participants must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.

Exclusion Criteria

* Subjects with a history of or concurrent diagnosis of other malignant tumors within the past 5 years.
* Unresolved toxicities from prior treatments exceeding Grade 1 according to Common Terminology Criteria (CTC) AE criteria, excluding alopecia.
* Major surgical procedures, significant traumatic injuries, or unhealed wounds or fractures within 28 days prior to the first dose.
* Any bleeding or hemorrhagic event of ≥ Grade 3 according to CTC AE criteria within 4 weeks prior to the first dose.
* Arterial or venous thrombotic events within 6 months prior to the first dose.
* Active gastric or duodenal ulcers, perforations, persistent positive fecal occult blood tests, ulcerative colitis, or other gastrointestinal bleeding conditions within 6 months prior to the first dose; or other bleeding conditions as assessed by the investigator.
* Hepatitis B virus (HBV)-infected patients unable to adhere to consistent antiviral therapy, or Hepatitis C virus (HCV)-infected patients (positive for HCV Ab or HCV RNA) deemed unstable by the investigator or requiring continued antiviral therapy without consistent adherence.
* History of substance abuse involving psychotropic drugs that cannot be discontinued or presence of psychiatric disorders.
* Symptomatic interstitial lung disease or conditions likely to cause drug-induced lung toxicity or related pneumonitis.
* Presence of any severe and/or uncontrolled diseases.
* Histological or cytological confirmation of other pathological types, such as acinar cell carcinoma, neuroendocrine carcinoma, or pancreatoblastoma.
* Tumors confirmed via imaging (CT or MRI) to have invaded major blood vessels, with the investigator deeming a high likelihood of fatal hemorrhage during the study.
* Tumors confirmed via imaging (CT or MRI) to have invaded the gastrointestinal tract, with a high risk of bleeding based on endoscopy and investigator assessment.
* Known central nervous system metastases and/or carcinomatous meningitis.
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage, as assessed by the investigator.
* History of severe allergic reactions to biologic agents or known hypersensitivity to any component of TQB2868 injection.
* Chronic treatment with systemic corticosteroids or other immunosuppressive agents within 28 days prior to the first dose, and continued use of such medications within 2 weeks after the first dose.
* Receipt of live attenuated vaccines within 28 days prior to the first dose or planned administration of live attenuated vaccines during the study.
* Systemic therapy required within 2 years prior to the first dose for any condition. Alternative therapies are not considered systemic therapy.
* Participation in other clinical trials involving anti-tumor drugs within 28 days prior to the first dose.
* Any comorbidities or conditions deemed by the investigator to pose severe risks to the subject's safety or the completion of the study, or any other reasons rendering the subject unsuitable for enrollment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henan Cancer Hospital

Zhengzhou, Henan, China

Site Status RECRUITING